Released Aug 7, 2025, after the close
10-Q filed Aug 8, 2025, 39 days after period end · 0001636422-25-000111
Q2 2025 · 10-Q
Revenue$80.72M$80.72M +6.3% vs Q2 2024+1.6% vs Q1 2025
Net Income-$40.98M-$40.98M N/M vs Q2 2024N/M vs Q1 2025
EPS Diluted-$0.59-$0.59 N/M vs Q2 2024N/M vs Q1 2025
Operating Income-$37,094,000N/M
Operating Cash Flowderived-$8,997,000N/M
Free Cash Flowderived-$8,767,000N/M
Margins · derived
Operating margin-46.0%−25.1 pt vs Q2 2024
Net margin-50.8%−33.0 pt vs Q2 2024
What the release said
The release
Same quarter
| Metric | Q2 2025 | Q2 2024 | Q2 2023 | Q2 2022 |
|---|---|---|---|---|
| Revenue | $80.72M | $75.90M | $73.21M | $70.63M |
| Net Income | -$40.98M | -$13.52M | -$32.61M | -$33.43M |
| EPS Diluted | -$0.59 | -$0.23 | -$0.58 | -$0.62 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Health Catalyst, Inc. · CIK 1636422 · Engraved from SEC EDGAR